- The agreement includes potential payments up to USD 570 million, with USD 48 million in upfront and near-term payments.
- CDR111 is a trispecific M-gager designed to target and deplete B cells in autoimmune diseases.
- The collaboration builds on previous work in retinal health, specifically geographic atrophy.
- Boehringer is investigating the technology in the VERDANT Phase 2 trial.
Agreement Overview
Boehringer Ingelheim and CDR-Life have entered a global licensing agreement to develop CDR111, a trispecific M-gager designed for autoimmune diseases. The deal includes potential payments up to USD 570 million, with USD 48 million in upfront and near-term payments, plus tiered royalties on future sales.
CDR111 and Its Potential
CDR111 is an antibody-based T-cell engager aimed at selectively targeting and depleting B cells to achieve immune system reset. Dysregulated B cells are central to many autoimmune and inflammatory conditions, such as lupus, multiple sclerosis, and certain forms of arthritis. This approach could have broad potential across multiple indications.
Previous Collaboration
The agreement builds on a successful collaboration between the companies on an investigational antibody fragment for retinal health. Boehringer has developed a molecule with technology licensed from CDR-Life, aimed at preserving vision in people with geographic atrophy. This molecule is currently being investigated in the VERDANT Phase 2 trial.
